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ABSTRACT  Purpose: Unifying terminology for the description of ocular surface 
disease (OSD) is vital for determining treatment responses and ensuring robust 
clinical trial outcomes. To date, there are no agreed parameters describing ‘activity’ 
and ‘damage’ phases of disease. Methods: A working group of international experts 
in OSD, oculoplastics, and uveitis from a range of backgrounds (university, teaching, 
district general and private hospitals) participated in a modified Delphi consensus-
building exercise (October 31, 2011 to March 20, 2015). Two steering group meetings 
took place in which factors based upon published literature were discussed and 
supplemented with anonymous web-based questionnaires to refine clinical indices 
according to ‘activity’ (reversible changes resulting directly from the inflammatory 
process) and/or ‘damage’ (persistent, >6 months duration) changes resulting from 
previously active disease that are cumulative and irreversible). 
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Results: The recommended set of clinical parameters for the assessment of OSD 
encompasses 68 clinical indices and 22 ancillary grading tools (in parenthesis) 
subdivided by anatomical domain as follows: 4(4) tear-film, eyelid 21(3), 17(3) 
conjunctiva, 15(10) cornea and 11(2) Anterior Chamber/Sclera. Of these; 17(2) were 
considered as measures of clinical activity, 27(3) as damage, 1(8) as measures of both 
activity and damage. Twenty-three clinical descriptors and 9 tools did not reach the 
threshold for inclusion into the main standard set. These were defined as ‘second tier’ 
parameters for use in special clinical settings. Conclusion: These core parameters 
provide the first description of ‘activity’ and ‘damage’ relevant to OSD and provide a 
platform for the future development of scoring scales for each parameter.  
 
 
KEY WORDS cornea, conjunctiva, Delphi process, disease activity, disease damage, 
disease scoring, disease staging, ocular surface disease 
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I. Introduction 
The ocular surface is a specialized mucosa comprising an epithelium and 
stroma extending from the mucocutaneous junction at the eyelid margin and including 
the tarsal, fornical and bulbar conjunctiva, limbus, and cornea.1 Obtaining nutrition 
largely from the tear film and vascular arcades, and for the cornea, from the aqueous 
humor, the system also includes associated adnexal structures, lacrimal glands, and 
eyelids. All components are linked by the continuity of the surface epithelia and 
through close interaction with innervation, endocrine, vascular, and immune systems. 
Disease processes affecting the ocular surface system, defined as ocular surface 
disease (OSD), have a diverse range of underlying pathologies, encompassing a 
spectrum of clinical entities, often with overlapping pathogeneses. Documentation of 
OSD includes the recording of physical signs of all components of the ocular surface 
system but also the posterior layers of the cornea, sclera and anterior chamber.  
The breadth of OSD sequelae is exemplified by conditions forming the 
progressive conjunctival scarring subgroup, such as mucous membrane pemphigoid 
(MMP), Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS-TEN) and graft-
versus-host disease (GVHD).2,3 These conditions are characterized by conjunctival 
inflammation often associated with destruction of the normal ocular surface 
architecture, fibrosis, dry eye disease and eyelid deformities leading to surface 
breakdown, vulnerability to infection, limbal epithelial stem cell destruction, corneal 
scarring, neovascularization and eventually ocular surface failure. Chronic SJS-TEN 
can additionally be accompanied by scleritis.4 
While OcMMP, SJS-TEN and GVHD are relatively rare compared to many 
OSDs, they serve as model disease platforms for quantifying the wealth of clinical 
signs for stratification according to ‘activity’ and ‘damage’ that may be generalizable 
across the whole spectrum of OSD. A range of scoring systems have been proposed 
for OcMMP, including conjunctival inflammation,5 scarring,6-8 methods for 
quantifying scarring,9 and for SJS-TEN the use of temporal-spacial staging (acute or 
chronic)10, 11 accompanied by ordinal scales for tear film, eyelid, corneal and 
conjunctival involvement; these scoring systems cannot be applied across all 
OSDs.3,11 ‘Function’ can also be used for documenting OSD indices, as illustrated by 
the dry eye and meibomian gland workshops.11-14 These existing scoring systems are 
not in routine clinical use.  
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Disease ‘activity’ or ‘damage’ can also be determined by classifying a range 
of clinical parameters into 1) ‘activity,’ in which clinical manifestations are reversible 
and result directly from the inflammatory process, in which disease remission occurs 
spontaneously or following treatment such as immunosuppression; or 2) ‘damage,’ in 
which clinical manifestations are persistent, i.e., are present for greater than 6 months 
duration, and result in permanent changes in anatomy, physiology, pathology or 
function.15 Damage results from previously active disease where changes are often 
cumulative and irreversible.15  
This method of scoring specifically benefits patients who present with early 
disease when the diagnosis is uncertain, and detailed investigation and/or prolonged 
follow-up would be required before the phenotype of the disease would manifest a 
diagnosis. A similar model is obtained from rheumatologic conditions in which early 
diagnostic criteria and the distinctions between disease ‘activity’ and ‘damage’ have 
been established and extrapolated to disease entities such as systemic lupus 
erythematosis, rheumatoid arthritis, and Sjögren syndrome.16-21 In such conditions, 
these terms are critical for defining relapse, remission and progression of disease, 
together with documenting treatment response, developing novel treatment response 
guidance, or ensuring robust outcomes for both small- and large-scale clinical 
trials.12,20,22,23 OSD is not absolutely synonymous with rheumatological conditions, 
and patient perceptions of OSD can influence the ocular surface severity score. For 
instance, the OSD patient may describe neuropathic pain that outweighs observed 
clinical signs, but influences the patient-reported outcomes of a putative ocular 
surface severity score. Defining ‘activity’ and ‘damage’ parameters provides an 
excellent foundation to begin the process of developing an ocular surface disease 
scoring system (OSDISS).  
To meet the same end point in OSD as has been achieved in rheumatology, 
unifying terminology to describe the stage of ‘activity’ and ‘damage’ is required in 
addition to agreement on the grading of each parameter to stage severity or 
progression of disease. One method for achieving this is a consensus statement 
derived through a Delphi process. Originally developed by the United States Air 
Force during the Cold War, the Delphi process is structured to obtain a consensus 
opinion from a group of experts.24 The advantage of this approach is its ability to 
gather information from multiple experts without the risk of giving greater weight to 
input from senior or more vocal individuals.25  
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The objective of our study is to integrate specialist OSD knowledge through 
use of a modified Delphi technique to obtain consensus on a set of core clinical 
domains for the assessment of OSD and categorize according to activity/damage 
domains. Ultimately, our aim is to develop measurable scales for each clinical 
parameter, evaluate patient-reported outcomes, validate, and internationally adopt an 
agreed OSDISS that could be employed generically across all OSDs, particularly in 
the early stages when the diagnosis is not established. 
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II. Methods 
The modified Delphi process was designed to conform to best practice 
described by Sinha and colleagues.25  
 
A. Steering Group Formation 
An expert steering group was established whose remit was to identify 
measurable disease parameters for consensus building. Experts were identified using 
inclusion criteria as described for the Dysfunctional Tear Syndrome Delphi process.12 
“Experts” met the following requirements: 
1. Active clinicians (ophthalmologists).  
2. Scientific contributions to clinical research on the ocular surface or expertise 
in ocular surface, as reflected by at least two of: peer-reviewed publications, 
other forms of written scientific communication, specialty meeting 
presentations, and membership in international ocular surface disease 
societies.  
3. Comprised international representation.  
4. Proficiency in English language to facilitate interaction.  
5. Ability to respond to sets of questionnaires and available to steering group 
meetings at the University of Birmingham, United Kingdom. 
 
Of the UK-based steering group members, panelists were selected to represent a 
cross-section of the geographical patient population centers identified through a 
surveillance study.26 Additional advisors with expertise in oculoplastics and uveitis 
were included to increase breadth of knowledge required for describing the adnexae 
and inflammatory eye diseases as part of the spectrum ocular surface system 
disorders. All but one of the 22 invited panelists accepted the invitation. 
 
B. Summary of the Modified Delphi Process 
A modified version of the Delphi process was used to obtain group consensus. 
This included the essential features of a consensus method described by Hunter and 
Jones.27 
• Anonymity – to avoid dominance of one individual within the group.  
• Multiple iterations – giving participants the chance to change their views.  
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• Controlled feedback – showing the distribution of the group response.  
• Statistical group response – expressing judgment using summary measures of 
the whole group response.  
 
The consensus building exercise was divided into 5 key work packages (WP). 
 
Work Package 1 (WP1): Preliminary Ballot 
The first web-based ballot (eFigure 1) consisted of a nonexhaustive 
itemization of possible clinical parameters for inclusion in a scoring tool, derived 
from modification of existing scoring systems for OSD.5-8,11-14,28-30 Steering group 
participants were encouraged to suggest additional variables for inclusion in the 
putative activity and damage OSD scoring system.  
 
Work Package 2 (WP2): The First Steering Group Meeting  
The Steering Group convened to discuss results of WP1 using the nominal 
group technique.27,31 During this meeting, each clinical parameter was discussed. The 
group was invited to vote again in light of the discussion as to whether the clinical 
parameter should be included. Each member of the group was given an opportunity to 
chair part of the session, ensuring even representation from all group members. In 
order to encourage the inclusion of as many of the parameters as possible, a majority 
vote was accepted for inclusion of the clinical variable to a putative list of activity and 
damage indicators.  
 
Work Package 3 (WP3): Web-based International Consultation 
The results of the first steering group meeting were used to create a web-based 
questionnaire (eFigure 2) and disseminated to an international group of OSD clinical 
specialists invited via an undisclosed recipient electronic-mail communication to 
members of the International Ocular Surface Society and UK Bowman Club via their 
administrative secretaries. Additional invitations were extended to advisory group 
specialists in uveitis (n,10) and oculoplastics (n,10) extrapolated from the 
International Uveitis Study Group (IUSG) and International Group of Oculoplastics 
Specialists, using the criteria outlined for the members of the OSD steering group. 
This questionnaire formed an anonymous specialist consultation where a minimum 
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number of participants (n=30) commensurate with other published Delphi processes 
were defined to ensure validity of the consultation exercise.12,32,33 
OSD specialist recipients were asked to rank the 76 agreed indices and 30 
ancillary grading tools over the 5 clinical domains (tear-film, eyelids, conjunctiva and 
fornices, cornea and sclera/anterior chamber [AC]) in the context of eight common or 
important clinical disease entities:  
1. Blepharitis 
2. Mucous membrane pemphigoid or other progressive cicatrizing 
conjunctivitis  
3. Bacterial keratitis 
4. Viral keratitis (e.g., herpetic keratitis) 
5. Dry eye disease 
6. Sjögren’s syndrome (primary or secondary) 
7. Corneal melt including peripheral ulcerative keratitis 
8. Chemical injury 
 
Participants were asked to consider the ‘best’ ancillary grading tool by 
“assuming you have all of these available” (see supplementary figure 2) and a gauge 
of the ‘real world’ scenario was examined by asking: “Which of these (these tools) do 
you have available?” Oculoplastics and uveitis specialist consultations were restricted 
to domains relevant to their subspecialties comprising tear film/conjunctiva-
fornices/cornea and cornea/anterior chamber-sclera, respectively.  
Based upon the variation among published ‘cut-off’ limits ranging from 60% 
to 80% to determine consensus, 12,34-38 a 75% cut-off of the upper and lower quartiles 
in order to balance definite agreement (“agree” or “strongly agree”), disagreement 
(“disagree” or “strongly disagree”) and areas of ambiguity was identified. A timeline 
of 10 weeks was set for completion. Information was anonymously populated into an 
Adobe Form Central data capture sheet (https://new.acrobat.com, 2013).  
 
Work Package 4 (WP4): Second Steering Group Meeting 
The results of the consultation questionnaire were presented at a second steering 
group meeting. The live anonymous web-based voting system using Adobe Form 
Central enabled unbiased arbitration during the following Expert workshops: 
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• Workshop A (WSA): Unclassified Clinical Parameters. Clinical parameters 
with ≥75% consensus were included into the scoring system; otherwise they 
were classed as ‘second-tier.’ Second-tier parameters were defined as 
parameters for specialist situations (but not essential for a general 
ophthalmology setting). 
• Workshop B (WSB): ‘Activity’ and ‘Damage’. The stratification of each 
parameter and grading tool into one of three activity-damage domain 
categories measuring 1) ”activity”, 2) “damage”, and 3) both “activity and 
damage” was undertaken. A ≥75% consensus was required for classification 
where activity was defined as reversible/medically modifiable manifestations 
or  damage as manifestations that are persistent (>6 months) and result from 
previously active disease. Parameters and tools that could not be successfully 
classified into an activity-damage domain, formed a fourth domain termed 
‘unclassified’ (either ‘activity’ or ‘damage’) and were subject to further 
consultation in WP5. 
 
Work Package 5 (WP5): Final Consultation Defining ‘Activity’ and ‘Damage’.  
Clinical parameters from WP5 Workshop B that remained unclassified were 
arbitrated through a final round of voting involving the OSD specialists where 
participants were asked to classify the ambiguous indices as 1) “activity,” 2) “damage,
” and 3) both “activity and damage.” A ≥70% consensus enabled direct definition of ‘
activity’ and ‘damage’ domains to ensure maximal classification of remaining 
parameters. The outcome dataset from Work Package 5 produced a consensus 
statement on a set of five core clinical domains for the assessment of OSD stratified 
across three activity-damage domains. 
 
 
C. Approvals 
Institutional review board approval was not required because the study did not 
involve patient or registry data and this was confirmed by the Research Support 
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Group Research Ethics Team (ref ERN_15-1195) at the University of Birmingham 
(UK). 
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III. Results 
A diagram of the work packages and summary of outcomes is outlined in 
Figure 1.  
 
A. WP1 and WP2: Preliminary Ballot and The First Steering Group 
Meeting. 
 Seventy-six clinical indices were subdivided into five domains: Tear film; 
Eyelids, Lid Margins and Meibomian Glands; Conjunctiva and Fornices; Cornea; 
Anterior Chamber and Sclera were disseminated as part of Work Package 1 
(Preliminary Ballot). The Ballot ‘included’ the majority of proposed indices, with 
highest agreement in the fornix subset versus the tear film (lowest) (Figure 2).  
  Twelve clinical parameters were rejected from across all domains and two 
were reclassified as a new category, “ancillary grading tools,” i.e. methods of 
examining and quantifying disease (see below). Fifteen new clinical parameters were 
added, giving rise to a revised total of 76 clinical indices (Figure 2). It was agreed that 
a list of 30 additional “ancillary grading tools” should be constructed and considered 
as part of the WP3 international consultation exercise (Table 1). A scoping exercise to 
define the availability of these tools in the Delphi responders’ clinical practice was 
proposed to be integrated into WP3. 
 
B. WP3: Web-based International Consultation  
 A total of 53 specialists responded (40 OSD, 5 oculoplastics, 8 uveitis) with 
most (47) practicing in a University Teaching Hospital. Specialists were from 8 
countries (Australia 10, Belgium 1, Germany 3, Slovenia 1, New Zealand 1, 
Singapore 2, United Kingdom 32 and United States 2, one person did not specify their 
country of origin in the anonymous form)  
Of the 76 clinical indices, 52 (68%) achieved ≥75% ranking for inclusion and 
none reached the 75% threshold for exclusion. 
 Twenty-two of 30 ancillary grading tools achieved the 75% threshold (Table 1, 
Figure 3). Table 1 also highlights the availability 13 (43%) ancillary grading tools that 
were available in clinical practice to >75% of participants.  
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C. WP4 and WP5: Second Steering Group Meeting and Final Consultation 
Workshop A: Unclassified Clinical Parameters 
 Twenty-four of the 76 clinical parameters did not reach the ≥75% threshold. 
After Steering Group discussion, anonymous web-based arbitration included a further 
15 unclassified indices and 1 novel clinical entity (scleral thinning) was introduced 
giving a total of 68 indices (Figure 3). The ten remaining indices formed ‘2nd tier’ 
clinical parameters.  
 The steering group arbitrated that ancillary grading tools that did not reach the 
>75% threshold became ‘2nd tier’ tools for use in refining scales in specialist 
situations (Figure 3)  
 
Workshop B and WP5: Activity and Damage Stratification  
 During WP4 Workshop B, one parameter (palpebral aperture) was considered 
to be a physiological or anatomical descriptor that was not amenable to classification 
into activity and damage domains and was therefore not put forward to the final 
consultation forming WP5. This parameter formed an ‘unclassified’ category.  
 Following completion of the final round of questionnaires, 17 clinical 
parameters and two ancillary grading tools (in parenthesis) were classified as a 
measure of “activity”: Tear film: 0(1), Lids: 4(0), Conjunctiva: 7(0), Cornea: 0(0), 
AC/Sclera: 6(1). Twenty-seven clinical parameters and 3 ancillary grading tools were 
classified as a measure of “damage”: Tear film: 0(0), Lids: 10(2), Conjunctiva:10(1), 
Cornea: 4(0), AC/Sclera: 3(0). One of the clinical parameters and 6 of the ancillary 
grading tools were classified as a measure of both “activity and damage” with 
photography appearing in 3 clinical domains (lids, conjunctiva, cornea). The 
remaining clinical parameters and ancillary grading tools formed 2nd tier for activity 
and damage: Tear film: 4(3), Lids: 7(0), Conjunctiva: 0(1), Cornea: 11(5), AC/Sclera: 
1(0). (Figure 4, eTable 1). 
 
IV. Discussion 
 This is the first international consensus statement on putative descriptors of 
OSD and discriminators of ‘activity’ and ‘damage’ providing a platform for 
standardizing terminology when describing disease staging and progression. This is of 
considerable importance for identifying response to treatment and to enable robust 
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outcome comparisons between clinical trials or gauging response to novel tissue 
specific therapeutic interventions.39 
 Current OSD scoring systems are disparate, with multiple systems describing 
specific disease entities. While OSD-specific questionnaires relating to symptoms 
have been validated,39 to date there is no generic consensus on accepted clinical 
indices and how these should be scored, independent of the underlying disease 
process. This is essential, as the overall end-stage for all OSD is ocular surface failure 
and, as such, it should be possible to assimilate a battery of clinical features and scales 
to apply broadly across numerous OSD processes, particularly at the early stages 
when the diseases may present with indistinguishable signs, e.g., red eye. To this end, 
we sought to establish an ‘OSD Toolbox’, where the clinician has the ability to select 
the most relevant ‘tools’ to accurately describe the clinical features of a patient who 
may not have a diagnosis or for whom the diagnosis is equivocal. This could provide 
the basis for stratifying the ‘Tools’ into descriptors of recognized disease entities. 
This process could allow retrospective analyses of clinical features at presentation, 
thereby identifying putative common features in stages of disease before the diagnosis 
is known. This methodology could enable clues to support earlier diagnosis and 
prediction of OSD clinical course thereby leading to earlier intervention and improved 
clinical outcomes. 
The use of the Delphi approach in the healthcare setting is well 
established12,40-42 and has been used effectively across multiple specialties 
(rheumatology,16,32,43 ophthalmology,12,31 palliative care,40 orthopedics,35 and 
anesthesiology36, 37). It excels when there is either a paucity of evidence, such as in 
the description of OSD, or when the available evidence is contradictory.27, 42 
Limitations include reliability and reproducibility, possibly due to group 
selection.42,44,45 To overcome this, we identified participants based upon geographical 
distribution of the British Ophthalmological Surveillance Unit respondent data to 
ensure even expert representation of steering group attendees from across the United 
Kingdom.26 As in other published literature, participant selection was non-random, so 
representativeness is not assured,42 but potential bias was minimized through the use 
of anonymous web-based questionnaires throughout the process. Where group 
discussions were held, opportunity was given for each participant to lead part of the 
group discussion to reduce the effect of a dominant individual.  
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Often the Delphi process is used when evidence is limited or absent in a given 
subject field, leading to the possibility of collective group error.41 Equally, the results 
may be in direct conflict with the available evidence. We included the majority of 
clinical parameters and ancillary grading tools, with the exclusion of very few indices. 
Since little has been excluded, collective group error has been attenuated, and the 
study has created an inclusive platform from which further refinements can be made. 
Work Package 2 saw a high level of agreement in Domain 5 (AC and Sclera), which 
has been the subject of a previous Delphi consensus endorsing reproducibility of the 
results of the Delphi process. 29 
High levels of agreement for were found for activity (conjunctival 
inflammation, foamy meibomian gland secretions, presence of anterior chamber cells, 
hypopyon) and damage (entropion, ectropion, horizontal forniceal involvement by 
fibrosis, iris atrophy). No clinical parameters or investigations were directly voted 
into the combined activity and damage domain. Some parameters failed reach 
sufficient consensus for classification as ‘activity’, ‘damage’ or ‘activity and 
damage’. An example of this is tear film breakup time. This reached a 66.6% 
consensus for ‘activity’ in WP4, but only 50% consensus in WP5. A similar 
phenomenon occurred in the Cornea Domain, with none of the parameters being 
classified as measures of ‘activity’. This is possibly because the votes were split 
across ‘activity’ and ’activity and damage’. Further iterations of the process are 
required for refinement. We acknowledge that  setting a higher threshold resulted in 
exclusion of some parameters. The threshold was reduced to 70% for work package 5 
to improve classification, but the Delphi process clearly highlighted significant 
disagreement among specialists, e.g., in corneal activity, and we believe this is likely 
to reflect the disparate nature of corneal disease. For this reason, no parameter was 
fully excluded, and those that did not meet a consensus were available in the reserve 
pool that was termed ‘second tier’. We believe that corneal disease activity will be 
more easily defined in a disease specific context, beyond the remit of this exercise and 
will be focus for future validation work. 
Following WP5, the distribution of votes among the remaining parameters 
highlighted sufficient uncertainty amongst participants such as the presence of 
filaments. This enabled these entities to default into a 2nd tier combined activity-
damage domain rather than being excluded from the dataset.  
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The current list should be considered a platform for further development. 
Indeed, future work is required to refine the ‘Tool Box’ of clinical features describing 
OSD with scales for quantifying each parameter to enable its use in more specific 
disease processes.12, 35-37 This will necessitate further group discussions, literature 
review, and definition of severity scales. Prospective collection of patient data, 
including patient-reported outcomes encompassing vision related quality of life and 
neuropathic pain (a clinical feature that has recently gathered considerable interest), 
are essential composites to computing an activity and damage score and generating an 
OSDISS. We recognize that the outcome of this Delphi process provides a ‘first step’ 
to achieving this goal and should not be seen as a final arbiter. It is hoped that by 
defining these in a disease-specific context, it will be clearer how to relate scales to 
activity or damage or both. This specifically benefits patients who present with early 
disease when the diagnosis is uncertain and only after detailed investigation and/or 
prolonged follow-up, the phenotype of the disease manifests a diagnosis. 
Furthermore, with wider application of certain ancillary tools, e.g., AS-OCT, this may 
alter the profile of how parameters and diseases are quantified.  
This study considered ‘activity’ and ‘damage’ in the context of inflammation. 
While inflammation is the major contributor in many ocular surface diseases, we 
acknowledge that dysfunctional innervation or the mechanical breakdown of the 
corneal surface, e.g., in recurrent corneal erosion syndrome, may themselves relate to 
‘activity’ and ‘damage’ independent of overtly manifest inflammation per se. There 
is, however, increasing awareness that all processes at a molecular level have an 
underlying inflammatory component, as tissue injury of any nature, whether 
exogenous or endogenous, will release cytokines, inflammatory mediators and 
promote recruitment of inflammatory cells. This has, for example, been recently 
recognized in the context of progressive conjunctival scarring in clinically quiescent 
eyes where neutrophils have been identified as critical in mediating disease 
progression.46,47 
While the breadth of this toolbox may appear daunting, it is hoped that this 
Delphi process has taken the first step in pulling disparate indices into a single arena 
and for the first time gaining agreement. The most obvious utility for the OSIDSS 
scales outside the research setting is the provision of a matrix from which electronic 
patient records (EPR) can be developed. The purpose of this study was not to create 
individual scales for each disease, enabling those in current use to be adopted for EPR 
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prior to disease specific validation exercises. Ultimately, the point of this exercise was 
to create an environment for further development. For instance, in forniceal scarring, 
we would propose the adoption of the fornix depth measurer to measure scarring, as 
this has been through an intra- and inter- observer validation exercise.9,48 In EPR 
development, this would be considered a continuous value that could be compared 
over time and for the purpose of recording damage. Conjunctival inflammation, 
however, may be considered through various ordinal scales, e.g., 1-4, 1-5 etc.5,49 Until 
such validation exercises have been completed, developers may elect to choose one or 
the other in order to facilitate EPR completion. In turn these may provide benchmark 
data for national data collection and audit exercise.  
 
V. Conclusion 
The validation of longitudinal collection of clinical ‘activity’ and ‘damage’ 
with grading scales correlated to measures of patient perception, experience, and 
reported outcomes of disease will provide a valuable objective resource for 
interrogating accurately described clinical features at presentation when diagnosis is 
equivocal. This will provide clues to earlier diagnosis, prediction of disease course, 
and improved clinical outcomes. It will also allow standardization of research data 
and a unified approach to objective assessment of treatment response, specifically to 
novel interventions in a clinical setting. 
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Figure legends 
 
Figure 1: Diagrammatic representation summarizing the work packages forming 
the OSD Delphi process.  
 
Figure 2: Summary of the results from WP1 and WP2. The results of the pre-
meeting questionnaire (WP1) were discussed and categorized after anonymized 
voting at the first steering group meeting (WP2). Fifteen new parameters were added, 
12 excluded and 2 were redeployed to a novel “ancillary grading tool” grouping 
(AGT). Some of the terms were altered at the first steering group meeting; ‘tear 
meniscus’ was changed to ‘tear meniscus height’, ‘anterior blepharitis’ was changed 
to ‘anterior lid margin disease’, ‘measurement of upper/lower fornix’ became 
‘measurement of upper/lower fornix central depth’, ‘central corneal ulceration’ and 
‘central corneal depth’ were changed to ‘localized corneal ulceration’ and ‘localized 
corneal depth’ respectively.  
 
Figure 3: Results of the second steering group meeting (WP3 and WP4 
Workshop A). Clinical parameters that met the ≥75% consensus threshold in the 
Web-based International Consultation (WP3) together with equivocal parameters that 
were positively considered by the Steering Group (WP4 WSA) are shown in column 
1. Equivocal clinical parameters that did not reach the ≥75% consensus were placed 
in a “second tier”. Similarly, Ancillary grading tools that achieved ≥75% consensus 
were included as tools essential for severity staging and the remainder were classified 
as ‘second tier’ to be used under specialist circumstances. 
[♦added at the second meeting,* Term amended]  
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Figure 4: Work Package 4 Workshop B and Work Package 5: Defining 
“activity” or “damage”. Attendees of the Second Steering Group Meeting (Work 
Package 4) were asked to participate in a web-based anonymous live voting exercise 
to determine clinical parameters and ancillary grading tools indicative of “activity” or 
“damage” or positively both “activity and damage”. A ≥75% consensus was required 
to be classified as such for WP4 (percentage vote for classification is in parenthesis). 
The remaining clinical parameters and ancillary grading tools were arbitrated by a 
wider consultation of OSD specialists (WP5). A ≥70% consensus was required for 
WP5 to ensure classification of a greater number of parameters. Parameters 
highlighted in red were successfully classified following WP5 and those that did not 
meet 70% consensus, were defaulted to ‘second tier’ “activity” and “damage” to be 
used under specialist circumstances.  
 
eFigure 1: Preliminary ballot (Work Package 1). The first web-based questionnaire 
that was disseminated to participants prior to Work Package 2.  
 
eFigure 2: Web-based International Consultation (WP3). Web-based International 
Questionnaire. Ocular Surface Disease Specialists were invited to vote on all 5 
domains. Uveitis experts were asked to respond to Domains 4 (Cornea) and 5 (AC 
and Sclera) only. Oculoplastics experts were asked to respond to the Domains 1 (Tear 
film), 2 (Eyelids lid margins and Meibomian glands) and 4 (cornea).   
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Table 1: Summary of Ancillary Grading Tools 
Considered Included 
Available in clinical 
practice 
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• Tear function index 
• Tear film osmolarity 
• Schirmer’s test 
• Fluorescein staining 
• Lissamine green staining 
• Meibography 
(meibomian gland drop 
out) 
• Fornix depth 
measurement 
• Confocal microscopy - 
tarsus 
• Confocal microscopy - 
conjunctiva 
• Confocal microscopy - 
cornea 
• Endothelial cell 
morphology and 
counting - specular 
microscopy 
Domain 1: Tear film 
• Tear film osmolarity 
• Schirmer’s test 
• Fluorescein staining 
• Lissamine green staining 
• B Scan ultrasound 
• Corneal topography 
e.g. Orbscan, pentacam 
• Endothelial cell 
specular microscopy 
• Fluorescein staining 
• Fluorescein 
angiography (but only 
20% had a specific 
protocol for the 
anterior segment) 
• Impression and brush 
cytology for retrieval 
of cells 
• Histological and cell 
staining 
• Immunostaining 
• OCT – spectral domain 
• Pachymetry 
• Photography 
Domain 2: Lids, lid 
margins and meibomian 
glands 
• Fornix depth 
measurement 
• Meibography 
• Photography 
 
Domain 3: Conjunctiva 
and fornices 
• Immunostaining 
• Fornix depth 
measurement 
• Photography 
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• Tissue biomarkers (cells, 
proteins, lipids, gene 
expression) 
• Biofluid biomarkers 
(tears, aqueous humor, 
blood, serum) 
• Impression and brush 
cytology for retrieval of 
cells 
• Histological and cell 
staining 
• Immunostaining 
• Indocyanine green 
angiography 
• Fluorescein angiography 
Domain 4: Cornea 
• Aethesiometry 
Orbscan/Pentacam 
• OCT - spectral domain 
• Pachymetry 
• Fluorescein staining 
• Lissamine green staining 
• Impression and brush 
cytology 
• Histological and cell 
staining 
• Photography 
• Endothelial cell specular 
microscopy 
 
• Schirmer’s test 
• Tonometry 
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• Aethesiometry (corneal 
sensation) 
• Corneal shape and 
thickness measurements; 
e.g. Orbscan and 
Pentacam 
• OCT - spectral domain 
• OCT - time domain 
• Wavefront aberrometry 
• Pachymetry 
• Corneal hysteresis 
• B-Scan Ultrasonography 
• High resolution anterior 
segment 
ultrasonography 
• Laser flare meter 
• Tonometry 
• Photography under 
standardized conditions 
Domain 5: AC and 
sclera 
• Laser flare meter 
• Anterior segment 
ultrasound 
Footnote: A list of all tools considered is shown together with a summary of the 
grading tools that met the 75% threshold after WP3 (International consultation) 
categorized according to clinical domain. Those that did not meet this threshold 
became second tier investigations. These were; biofluid biomarkers, B-scan 
ultrasonography, Confocal microscopy (conjunctival), confocal microscopy (corneal), 
confocal microscopy (tarsal), corneal hysteresis, fluorescein angiography, 
indocyanine green angiography, OCT (time domain), tear function index, tissue 
biomarkers, tonometry, wavefront aberrometry. Availability of listed tools in clinical 
practice for >75% respondents is also shown. (Abbreviations: OCT, optical coherence 
tomography). 
 
Describing the Problem – ‘To Define Ocular Surface Disease 
Parameters According to ‘Activity’ and ‘Damage’’ 
Work Package 1: Preliminary Ballot [Supplementary Figure 1] 
Work Package 2: The First Steering Group Meeting (2012) [Figure 2] 
Work Package 3: Web-based International Consultation [Supplementary 
Figures 2 & 3] 
• 13 Clinical parameters excluded 
• 2 Clinical parameters became ancillary grading tools  
• 15 New clinical indices Added (new total 76) 
• 30 (28+2) Ancillary grading tools added  
Work Package 4: Second Steering Group Meeting (2013) [Figure 3 & 
Supplementary Figure 4] 
• 14/24 equivocal clinical indices included,, 1 added. 
• Activity and Damage vote for remaining indices and 
tools 
• Opinion poll, no clinical parameters excluded, 4 received 
less than majority vote for inclusion.  
• 76 preliminary clinical parameters (literature review)  
• 52 clinical parameters included (24 equivocal) 
• None excluded 
• 17 Ancillary grading tools included 
• Remaining clinical parameters / tools became ‘second 
tier’’.  
Final output  – Ocular Surface Disease Descriptors of ‘Activity’ and 
‘Damage’ [Figure 4] 
Work Package 5: Final Consultation (2015) 
• 9/30 unclassified activity and damage indices included. 
Figure 1
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Tear film debris 
Peripheral ulcerative keratitis: degree of 
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Conjunctiva 
Conjunctival inflammation (with each outer 
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Upper fornix 
Measurement of upper fornix central depth 
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Lid margin irregularity 
Abnormal vascularity 
Anterior lid margin disease 
Medial Marx’s line 
Central Marx’s line 
Lateral Marx’s line 
Lashes 
Lash loss 
Trichiasis 
Dystichiasis 
Meibomian glands 
Pouting/plugging 
Opaque/scarred 
Meibomian gland orifice retroplacement 
Visibility of acini  
Concretions 
Chalazion formation  
Foam  
Quality of secretions 
Included  
InflammaDry  
Schirmer’s test (to ancillary grading 
tools)  
Tear film osmolarity (to ancillary 
grading tools) 
Tear film break up time 
Tear Meniscus Height 
Filaments 
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Conjunctival keratinization (also on 
conjunctiva and kept there)  
Corneal Ischemia 
Endothelial guttatae 
Sensation  
Punctate keratopathy  
Conjunctivalization  
Neovascularization (peripheral 
involvement) 
Neovascularization (encroaching on the 
visual axis)  
Corneal epithelial edema 
Corneal stromal edema  
Corneal opacification/scarring 
Corneal opacification/scarring encroaching 
on the visual axis 
Localized corneal thinning (no ulceration)  
Localized corneal ulceration 
Localized corneal ulcer depth  
Descemet's folds 
Reduced endothelial cell count (clinically 
apparent)  
Graft-host interface changes  
Nil Anterior synechiae (peripheral or 
central)  
Iris atrophy 
Intra-ocular pressure 
Anterior Chamber 
Keratitic precipitates 
Anterior chamber cells 
Flare  
Hypopyon 
Posterior synechiae 
Iris 
Iris nodules 
Sclera 
Anterior scleritis 
Posterior scleritis 
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Figure 2
Tear Meniscus Height 
Tear Film Debris  
Filaments 
  
 
Conjunctival chalasisu 
 
Lid margin reflex distances (one and 
two) 
Concretions 
Standardized meibomian gland 
expressibility 
Lid vascularityu 
 
Lid position  
Palpebral aperture 
Lid margins  
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Completeness of the blink cycle 
Lagophthalmos 
Lid malposition 
Entropion 
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Lid margins  
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Meibomian glands 
Pouting/plugging 
Orifice retroplacement 
Quality of secretions 
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Corneal ischemia 
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Punctate keratopathy  
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Neovascularization (peripheral 
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Neovascularization (encroaching on the 
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Corneal epithelial edema 
Corneal stromal edema  
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on the visual axis 
Localized corneal thinning (no ulceration)  
Localized corneal ulceration  
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Descemet's folds 
Iris nodules Scleral thinningu 
 
Anterior Chamber 
Keratitic precipitates 
Cells 
Flare  
Hypopyon 
Anterior synechiae (peripheral or central)  
Posterior synechiae 
Iris 
Iris atrophy  
 
Sclera 
Anterior scleritis 
Posterior scleritis 
Other 
Intraocular pressure  
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Impression and brush cytology 
Histological and cell staining 
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Corneal topography 
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High resolution anterior segment 
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Conjunctiva 
Inflammation  
Bulbar ulceration  
Limbitis  
Mucus 
Keratinization  
Punctate staining  
Papillae 
Follicles  
Ocular mobility 
Limitation in mobility 
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Horizontal involvement by fibrosis 
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Immunostaining 
Fornix depth measurement 
Photography  
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Tear film osmolarity 
Fluorescein staining 
 
Lissamine green staining 
Schirmer’s test  
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Tear function index  
Biofluid biomarkers 
Tarsal confocal microscopy 
Conjunctival confocal microscopy  
Tissue biomarkers 
Corneal confocal microscopy 
Fluorescein angiography 
Indocyanine green angiography 
Time domain OCT  
Wavefront abberometry  
Corneal hysteresis  
 
B-scan ultrasonography 
Tonometry   
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Photography (91.6%) 
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Fornix depth measurement (83.3%) 
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Lid margins  
Anterior lid margin disease (83%) 
 
Meibomian glands 
Pouting/plugging (75%) 
Foam (100%) 
Quality of secretions (91.7%) 
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Neovascularization (visual axis)  
Corneal epithelial edema 
Corneal stromal edema  
Localized corneal thinning (no 
ulceration)  
Localized corneal ulceration (loss of 
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Descemet's folds 
Graft-host interface changes 
 
Endothelial cell specular microscopy 
Aethesiometry  
Corneal topography 
Spectral domain OCT 
Pachymetry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impression and brush cytology (81.8%) 
Histological and cell staining (81.8%) 
Photography (90.9%) 
Fluorescein staining (90.9%) 
Lissamine green staining (90.9%) 
 
Conjunctivalization (90.9%) 
Corneal opacification/scarring (81.8%) 
Corneal opacification/scarring 
encroaching on the visual axis (81.8%) 
Endothelial guttata  (90.9%) 
 
 
Anterior Chamber 
Posterior synechiae 
 
 
 
 
  
IOP (91.7%) 
 
 
 
 
 
 
 
 
 
High resolution anterior segment 
ultrasound (83.3%) 
 
Anterior Chamber 
Anterior synechiae (peripheral or 
central) (75%) 
Iris 
Iris atrophy (100%) 
 
Sclera 
Scleral thinning (72.5%) 
 
 
 
 
 
Anterior Chamber 
Cells (100%) 
Flare (75%) 
Hypopyon (100%) 
Keratic precipitates (70%) 
 
Sclera 
Anterior scleritis (91.7%) 
Posterior scleritis (83.3%) 
 
Laser flare meter (80%)  
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Figure 4
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WP4 WSB WP5 WP4 WSB WP5 WP4 WSB WP5 Final Category 
Activity (%) 
Activity 
(%) Damage(%) Damage(%) 
Activity and 
Damage (%) 
Activity and 
Damage 
(%)   
Domain 1: Tear Film                
Tear film break up time 66.6 50 8.3 2.5 25 47.5 2nd Activity/Damage 
Tear meniscus height 41.7 37.5 25 32.5 33.3 30 2nd Activity/Damage 
Tear film debris 58.3 57.5 8.3 10 33.3 32.5 2nd Activity/Damage 
Filaments 58.3 57.5 8.3 10 33.3 32.5 2nd Activity/Damage 
Tearfilm osmolarity 75   8.3   16.7   Activity 
Schirmer's test 16.7 32 41.7 40 41.7 35 2nd Activity/Damage 
Fluorescein staining 25 42.5 25 10 50 47.5 2nd Activity/Damage 
Lissamine green staining 25 42.5 25 10 50 47.5 2nd Activity/Damage 
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WP4 WSB WP5 WP4 WSB WP5 WP4 WSB WP5 Final Category 
Activity 
(%) 
Activity 
(%) Damage(%) Damage(%) 
Activity and 
Damage (%) 
Activity and 
Damage (%)   
Domain 2: Eyelids, lid margins 
and meibomian glands               
Palpebral aperture 8.3   25   66.7   Unclassified 
Completeness of the blink cycle 8.3 5 41.7 32.5 50 57.5 2nd Activity/Damage 
Lagophthalmos 8.3 15 50 70 41.7 15 2nd Activity/Damage 
Lid malposition 0 7.5 66.7 80 33.3 12.5 Damage 
Entropion 8.3   91.7   0   Damage 
Ectropion 8.3   91.7   0   Damage 
Lid margin irregularity 8.3   83.3   8.3   Damage 
Lash Loss 8.3   83.3   8.3   Damage 
Trichiasis 8.3   91.7   0   Damage 
Dystichiasis 8.3   91.7   0   Damage 
Anterior lid margin disease 83   17   0   Activity 
M. Gland pouting/plugging 75   8.5   16.7   Activity 
M. Gland opaque/scarred 0   75   25   Damage 
M. Gland orifice retroplacement 0   75   25   Damage 
M. Gland visibility of acini 41.7 42.5 33.3 10 25 47.5 2nd Activity/Damage 
Chalazion formation 41.7 42.5 25 47.5 33.3 10 2nd Activity/Damage 
Foam 100   0   0   Activity 
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M.Gland expressibility 66.7 47.5 0 10 33.3 42.5 2nd Activity/Damage 
Lid margin thickening 41.7 42.5 8.3 10 50 47.5 2nd Activity/Damage 
Lid margin vascularity 41.7 42.5 8.3 10 50 47.5 2nd Activity/Damage 
Position of Marx's line  8.3 5 58.3 72.5 33.3 12.5 Damage 
Fornix depth measurement 0   83.3   16.7   Damage 
Meibography 0   83.3   16.7   Damage 
Photography 8.3   0   91.6   Activity/Damage 
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WP4 WSB WP5 WP4 WSB WP5 WP4 WSB WP5 Final Category 
Activity (%) 
Activity 
(%) Damage(%) Damage(%) 
Activity and 
Damage (%) 
Activity and 
Damage 
(%)   
Domain 3: Conjunctiva 
and fornices               
Conjunctival inflammation 90.9   9.1   0   Activity 
Bulbar ulceration  63.3 75 18.2 0 18.2 15 Activity 
Limbitis 90.9   9.1   0   Activity 
Mucus 81.8   18.2   0   Activity 
Bulbar conjunctival 
keratinisation 9.1  10 72.7 82.5  18.2 7.5  Damage 
Conjunctival punctate 
staining 63.3 72.5 18.2 5 18.2 22.5 Activity 
Papillae 63.3 82.5 9.1 12.5 27.4 5 Activity 
Follicles 81.8   9.1   9.1   Activity 
Upper fornix central depth 9.1   81.8   9.1   Damage 
Upper fornix number of 
symblephara 0   90.9   9.1   Damage 
Upper fornix horizontal 
involvment by symblephara 0   90.9   9.1   Damage 
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involvement by fibrosis 0   100   0   Damage 
Lower fornix central depth 0   90.9   9.1   Damage 
Lower fornix number of 
symblephara 0   90.9   9.1   Damage 
Lower fornix horizontal 
involvment by symblephara 0   90.9   9.1   Damage 
Lower fornix horizontal 
involvement by fibrosis 0   100   0   Damage 
Limitation of mobility 0 2.5 63.3 72.5 36.4 25 Damage 
Immunostaining 54.5 27.5 9.1 52.5 36.4 20 2nd Activity/Damage 
Fornix depth measurement 0 0 63.3 82.5 36.4 17.5 Damage 
Photography 18.2   0   82.8   Activity/Damage 
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WP4 WSB WP5 WP4 WSB WP5 WP4 WSB WP5 Final Category 
Activity (%) 
Activity 
(%) Damage(%) Damage(%) 
Activity and 
Damage (%) 
Activity and 
Damage 
(%)   
Domain 4: Cornea               
Corneal sensation  18.2 10 45.5 65 36.4 20 2nd Activity/Damage 
Punctate keratopathy 54.5 65 36.4 5 9.1 30 2nd Activity/Damage 
Conjunctivalisation 9.1   90.9   0   Damage 
Neovascularisation 
(peripheral) 18.2 7.5 18.2 37.5 63.6 55 2nd Activity/Damage 
Neovascularisation (visual 
axis) 18.2 7.5 18.2 37.5 63.6 55 2nd Activity/Damage 
Epithelial oedema 18.2 50 18.2 15 63.6 35 2nd Activity/Damage 
Stromal Oedema 9.1 32.5 18.2 17.5 72.7 50 2nd Activity/Damage 
Corneal 
opacification/scarring 
(peripheral) 0   81.8   18.2   Damage 
Opacification/scarring (visual 
axis) 0   81.8   18.2   Damage 
Localised thinning (no 
ulceration) 9.1 7.5 72.7 55 18.2 37.5 2nd Activity/Damage 
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Localised ulcer depth 
(thinned cornea) 18.2 17.5 27.2 30 54.5 52.5 2nd Activity/Damage 
Descemet’s folds 27.2 55 9.1 7.5 63.6 37.5 2nd Activity/Damage 
Graft-host interface changes 9.1 7.5 27.2 27.5 63.6 65 2nd Activity/Damage 
Endothelial guttae 0   90.9   9.1   Damage 
Specular microscopy 9.1 0 72.7 55 18.2 45 2nd Activity/Damage 
Impression/brush cytology 18.2   0   81.8   Activity/Damage 
Histological/cell staining 18.2   0   81.8   Activity/Damage 
Anaesthesiometer 0 5 54.5 67.5 45.5 27.5 2nd Activity/Damage 
Corneal shape/ thickness 
measurements 0 5 54.5 47.5 45.5 47.5 2nd Activity/Damage 
Optical coherence 
tomography 9.1 5 18.2 30 72.7 65 2nd Activity/Damage 
Pachymetry 9.1 7.5 18.2 27.5 72.7 65 2nd Activity/Damage 
Fluorescein staining 9.1   0   90.9   Activity/Damage 
Lissamine green staining 9.1   0   90.9   Activity/Damage 
Photography  0   9.1   90.9   Activity/Damage 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
WP4 WSB WP5 WP4 WSB WP5 WP4 WSB WP5 Final Category 
Activity (%) 
Activity 
(%) Damage(%) Damage(%) 
Activity and 
Damage (%) 
Activity and 
Damage 
(%)   
Domain 5: AC and Sclera               
Keratic Precipitates 58.3 70 0 5 41.7 25 Activity 
Anterior chamber cells 100   0   0   Activity 
Flare 75   0   25   Activity 
Hypopyon 100   0   0   Activity 
Anterior synechiae 
(peripheral/central) 0   75   25   Damage 
Posterior synechiae 0 12.5 50 50 50 27.5 2nd Activity/Damage 
Iris atrophy 0   100   0   Damage 
Intraocular pressure 8.3   0   91.7   Activity/Damage 
Anterior Scleritis 91.7   0   8.3   Activity 
Posterior scleritis 83.3   0   16.7   Activity 
Scleral thinning 0 7.5 70 72.5 30 20 Damage 
Anterior segment 
ultrasonography  16.7   0   83.3   Activity/Damage 
Laser flare meter 50 80 0 20 50 0 Activity 
